{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:04:57Z","timestamp":1769709897113,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare overall survival (OS) and progression-free survival (PFS) between surgical resection and non-surgical therapy in initially unresectable Cholangiocarcinoma (CCA) patients who achieved radiologic\/MDT-confirmed resectability after PD-1\/PD-L1 inhibitors plus TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of 47 patients with initially unresectable CCA admitted between June 2020 and December 2024. Based on post-conversion treatment strategies, patients were divided into non-surgical resection (NR) and surgical resection groups (SR). We collected detailed baseline clinical data, treatment-related parameters, and long-term survival outcomes for all participants. Overall survival (OS) and progression-free survival (PFS) were compared between groups, with recurrence-free survival (RFS) analyzed in the SR. Cox regression was used to identify prognostic risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study enrolled a total of 47 patients, including 23 in the SR and 24 in the NR. No significant differences were observed in baseline data between the two groups before conversion therapy. In the SR, the median overall survival (OS) was not reached, with 1-, 2-, and 3-year OS rates of 95.7%, 68.5%, and 68.5%, respectively. These survival outcomes were significantly superior to those observed in the NR, where the median OS was 28.5 months, and the 1-, 2-, and 3-year OS rates were 91.7%, 51.4%, and 17.6%, respectively (P = 0.026). Additionally, the SR exhibited a significantly longer median progression-free survival (PFS) of 19 months, with corresponding 1-, 2-, and 3-year PFS rates of 87.0%, 40.2%, and 25.2%. In contrast, the NR had a median PFS of 13.5 months and 1-, 2-, and 3-year PFS rates of 61.6%, 12.4%, and 12.4%, respectively (P = 0.025). Among patients in the SR, 21 cases (91.3%) achieved R0 resection, with no surgery-related mortality reported. The 1-, 2-, and 3-year recurrence-free survival (RFS) rates in this subgroup were 54.7%, 39.0%, and 29.3%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For patients with initially unresectable CCA, PD-1\/PD-L1 inhibitors plus TKIs can successfully downstage the tumor. Conversion surgery is safe and feasible, and surgical treatment can improve patients\u2019 OS and PFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1753437","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:10Z","timestamp":1769668870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1\/PD-L1 inhibitors plus TKIs"],"prefix":"10.3389","volume":"17","author":[{"given":"Zengpeng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.34541","article-title":"The multidisciplinary management of cholangiocarcinoma","volume":"129","author":"Ohaegbulam","year":"2023","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2048416","article-title":"Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy","volume":"54","author":"Deng","year":"2022","journal-title":"Ann Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002013","article-title":"Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study","volume":"111","author":"Zheng","year":"2025","journal-title":"Int J Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"LANCET"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17392-9","article-title":"Laparoscopic extended segmentectomy 8 with right hepatic vein resection after conversion therapy for advanced intrahepatic cholangiocarcinoma","author":"Tan","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"TPS4198","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4198","article-title":"Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence","volume":"42","author":"Sadagopan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104901","DOI":"10.3748\/wjg.v31.i15.104901","article-title":"Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946861","article-title":"Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: A real-world retrospective study in China","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.11.005","article-title":"Cholangiocarcinoma targeted therapies: mechanisms of action and resistance","volume":"195","author":"Ellis","year":"2025","journal-title":"Am J Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0486","article-title":"Reprogramming the intrahepatic cholangiocarcinoma immune microenvironment by chemotherapy and CTLA-4 blockade enhances anti-PD-1 therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/biom14080969","article-title":"Proteomics and bioinformatics identify drug-resistant-related genes with prognostic potential in cholangiocarcinoma","volume":"14","author":"Kerdkumthong","year":"2024","journal-title":"Biomolecules"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001540","article-title":"Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.5582\/bst.2024.01286","article-title":"mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC\/GS\/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer: A single-center retrospective cohort study","volume":"18","author":"Sun","year":"2025","journal-title":"Biosci Trends"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03466-8","article-title":"Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study","volume":"72","author":"Zhu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2034785","article-title":"Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned","volume":"31","author":"Mayr","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1397827","article-title":"Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-020-02031-5","article-title":"Conversion surgery for initially unresectable biliary Malignancies: a multicenter retrospective cohort study","volume":"50","author":"Noji","year":"2020","journal-title":"Surg Today"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000738","article-title":"Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer","volume":"109","author":"Liang","year":"2023","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.12.026","article-title":"Prognostic impact of the metastatic lymph node number in intrahepatic cholangiocarcinoma","volume":"172","author":"Kim","year":"2022","journal-title":"Surgery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: A single-arm, open-label, phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:11Z","timestamp":1769668871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1753437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1753437"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1753437","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1753437"}}